Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

August 12, 2022

Study Completion Date

September 8, 2022

Conditions
DyslipidemiasHigh CholesterolHypercholesterolemia
Interventions
DRUG

Obicetrapib

tablets

DRUG

Ezetimibe 10mg

capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.

OTHER

Obicetrapib placebo

tablets; no active ingredient

OTHER

Ezetimibe placebo

capsules; no active ingredient

Trial Locations (16)

31406

Meridian Clinical Research - Savannah, GA, Savannah

32127

Progressive Medical Research, Port Orange

33024

A & R Research Group, LLC, Pembroke Pines

34471

Ocala Cardiovascular Research, Ocala

42303

Research Integrity LLC, Owensboro

43213

Aventiv Research, Inc., Columbus

44240

Summit Research Group, LLC, Munroe Falls

45219

Meridian Clinical Research- Springdale, OH, Cincinnati

46260

Midwest Institute for Clinical Research, Indianapolis

48085

Oakland Medical Research Center, Troy

59701

Mercury Street Medical, Butte

60005

Northwest Heart Clinical Research, LLC, Arlington Heights

60101

Biofortis, Inc, Addison

83642

Velocity Clinical Research, Meridian

90057

Velocity Clinical Research - Westlake d.b.a National Research Institute, Los Angeles

91325

Valley Clinical Trials, Inc., Northridge

Sponsors
All Listed Sponsors
lead

NewAmsterdam Pharma

INDUSTRY

NCT05266586 - Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy | Biotech Hunter | Biotech Hunter